Financings
MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition
MindBio Therapeutics Corp.
Executive Summary
- Date: April 13, 2026
- Headline: MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition
- Core Announcement: Completion of "Intox Collect" software enabling voice/facial recognition data collection for CNS substances. AI model trained on >50 million data points (targeting 150 million).
- Hardware Roadmap: Edge AI hardware-software kiosk prototype nearing completion; field testing scheduled for late Q2 2026.
- Financing Correction: Clarification of April 1, 2026 private placement. Cash finder's fees paid: $74,983.97. Finder Warrants issued: 124,973 at $0.80 exercise price (36-month term).
- Capital Raise: Upsized private placement to $1.5 million total gross proceeds supports development and working capital.
Material Impact
- Operational Progress: Confirms the company is executing on its February 2026 pivot from clinical drug trials (MB22001) to AI-based workplace safety diagnostics. However, this is a continuation of previously announced strategy rather than new information.
- Financial Impact: The financing correction reveals significant cash fees ($75k) and warrant issuance associated with the capital raise. This increases the effective cost of capital without generating immediate revenue.
- Revenue Reality: No commercial contracts or revenue are disclosed. The technology remains in prototype/testing phase (Q2 2026).
- Risk Profile: The news does not address the fundamental solvency risk highlighted in December 2025 financials (negative equity of -$2M, high burn rate). It extends runway but increases dilution.
- Market Expectation: The market was already aware of the financing (announced March/April) and the technology pivot (announced February). This release is administrative confirmation.
MBIO · Price
Company Overview
- Overview: MindBio Therapeutics Corp. is a clinical-stage biotechnology company that has pivoted to AI-driven digital health diagnostics following negative Phase 2B results for its lead drug candidate.
- Flagship Project (Legacy): MB22001 (Microdosed LSD for Major Depressive Disorder). Phase 2B trial completed November 2025 showed no statistical superiority over placebo.
- Flagship Project (Current): Intox Collect™ / Edge AI Platform. Voice and facial recognition software to detect intoxication in workplace settings (mining, aviation). Currently in prototype/testing phase with no commercial revenue.
More from MindBio Therapeutics Corp.
Jun 09, 2026 · 07:00